New White Paper Calls for NHS Cannabis Pilot and Parliamentary Inquiry Into the Industry

Integrating Medical Cannabis into NHS Care: A Better Outcome for Government, Society, and Patients, available to download now for free, calls for a national NHS pilot programme, an updated NICE review of cannabis-based medicinal products (CBPMs), and a formal Parliamentary inquiry into the barriers to NHS access. 

The economic case

The paper’s economic modelling estimates that structured NHS access could generate an illustrative annual benefit to the state of between £204 million and £234 million. 

These potential savings are spread across five areas including a reduced demand on conventional prescriptions, fewer GP and secondary care consultations, increased employment and the associated tax revenues, reduced welfare payments, and reduced opioid-related costs, which the modelling places at between £20 million and £50 million of the total range.

Rather than provide precise predictions, the authors state clearly that these are scenario-based estimates aimed at highlighting the potential economic benefits at a time when the NHS desperately needs to cut costs. 

They argue that it is precisely because of the uncertainty surrounding the cost savings that a funded evidence-gathering programme is necessary. 

Restricted access

The paper draws directly on the case of Oliver Robinson, referenced in the context of a Coroner’s report that attracted national media attention. 

It argues that this was not as an isolated tragedy but as a structural consequence. With an estimated 140,000 patients now accessing medical cannabis in the UK through private clinics, up from roughly 100,000 a year ago, the population of people exposed to the financial pressure associated with private treatment is significant. 

For those who cannot sustain private costs, the alternative is not abstention but diversion to the unregulated market, without pharmaceutical-grade quality controls or clinical oversight.

Germany as the reference point

Bedrocan contributes a detailed account of Germany’s §31(6) SGB V reimbursement framework, which has operated since 2017. Under that model, patients can receive cannabis-based treatment through statutory health insurance on a case-by-case clinical basis, without requiring a population-level benefit determination of the kind NICE produces for conventional drug appraisals. 

The BfArM has run a companion scientific survey alongside the framework since its introduction, building a real-world evidence base in parallel with clinical delivery rather than as a precondition for it.

Three recommendations

As a solution to these structural issues, the paper proposes three concrete measures:

• A national NHS medical cannabis pilot programme would generate UK-specific real-world evidence under standardised clinical conditions and establish the cost-effectiveness data that commissioners and NICE require before population-level adoption. 
• An updated NICE review of CBPMs, reflecting eight years of evidence published since legalisation, would address the gaps that have allowed NHS exclusion to persist even as private prescribing has scaled to serve over 100,000 patients. 
• Finally, a Parliamentary inquiry into the barriers to NHS access would place responsibility for the current situation in the public record and create political accountability for whether it changes.

The white paper is available to download from UPA’s website, for free, here.